Intra-tumor Genetic Heterogeneity and Alternative Driver Genetic Alterations in Breast Cancers with Heterogeneous HER2 Gene Amplification
Overview
Authors
Affiliations
Background: HER2 is overexpressed and amplified in approximately 15% of invasive breast cancers, and is the molecular target and predictive marker of response to anti-HER2 agents. In a subset of these cases, heterogeneous distribution of HER2 gene amplification can be found, which creates clinically challenging scenarios. Currently, breast cancers with HER2 amplification/overexpression in just over 10% of cancer cells are considered HER2-positive for clinical purposes; however, it is unclear as to whether the HER2-negative components of such tumors would be driven by distinct genetic alterations. Here we sought to characterize the pathologic and genetic features of the HER2-positive and HER2-negative components of breast cancers with heterogeneous HER2 gene amplification and to define the repertoire of potential driver genetic alterations in the HER2-negative components of these cases.
Results: We separately analyzed the HER2-negative and HER2-positive components of 12 HER2 heterogeneous breast cancers using gene copy number profiling and massively parallel sequencing, and identified potential driver genetic alterations restricted to the HER2-negative cells in each case. In vitro experiments provided functional evidence to suggest that BRF2 and DSN1 overexpression/amplification, and the HER2 I767M mutation may be alterations that compensate for the lack of HER2 amplification in the HER2-negative components of HER2 heterogeneous breast cancers.
Conclusions: Our results indicate that even driver genetic alterations, such as HER2 gene amplification, can be heterogeneously distributed within a cancer, and that the HER2-negative components are likely driven by genetic alterations not present in the HER2-positive components, including BRF2 and DSN1 amplification and HER2 somatic mutations.
Fang K, Ohihoin A, Liu T, Choppavarapu L, Nosirov B, Wang Q Genome Med. 2024; 16(1):134.
PMID: 39558215 PMC: 11572372. DOI: 10.1186/s13073-024-01407-3.
Jia Y, Liu M, Liu H, Liang W, Zhu Q, Wang C Cancer Biol Ther. 2024; 25(1):2425134.
PMID: 39555702 PMC: 11581156. DOI: 10.1080/15384047.2024.2425134.
Jacobs S, Wang Y, Abraham J, Feng H, Montero A, Lipchik C Breast Cancer Res. 2024; 26(1):69.
PMID: 38650031 PMC: 11036567. DOI: 10.1186/s13058-024-01823-8.
Impact of Resistance on Therapeutic Design: A Moran Model of Cancer Growth.
Lacy M, Jenner A Bull Math Biol. 2024; 86(4):43.
PMID: 38502371 PMC: 10950993. DOI: 10.1007/s11538-024-01272-6.
In Vitro MRS of Cells Treated with Trastuzumab at 1.5 Tesla.
Guz W, Podgorski R, Bober Z, Aebisher D, Truszkiewicz A, Olek M Int J Mol Sci. 2024; 25(3).
PMID: 38338997 PMC: 10855746. DOI: 10.3390/ijms25031719.